- Home
- MASI vs BPMC Comparison
MASI vs BPMC Comparison
Compare MASI & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MASI
- BPMC
- Stock Information
- Founded
- MASI 1989
- BPMC 2008
- Country
- MASI United States
- BPMC United States
- Employees
- MASI N/A
- BPMC N/A
- Industry
- MASI Medical/Dental Instruments
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- MASI Health Care
- BPMC Health Care
- Exchange
- MASI Nasdaq
- BPMC Nasdaq
- Market Cap
- MASI 8.2B
- BPMC 8.3B
- IPO Year
- MASI 2007
- BPMC 2015
- Fundamental
- Price
- MASI $164.79
- BPMC $128.40
- Analyst Decision
- MASI Buy
- BPMC Buy
- Analyst Count
- MASI 6
- BPMC 20
- Target Price
- MASI $187.00
- BPMC $127.82
- AVG Volume (30 Days)
- MASI 579.3K
- BPMC 3.5M
- Earning Date
- MASI 08-05-2025
- BPMC 07-31-2025
- Dividend Yield
- MASI N/A
- BPMC N/A
- EPS Growth
- MASI N/A
- BPMC N/A
- EPS
- MASI N/A
- BPMC N/A
- Revenue
- MASI $2,126,800,000.00
- BPMC $562,121,000.00
- Revenue This Year
- MASI N/A
- BPMC $44.46
- Revenue Next Year
- MASI $7.74
- BPMC $32.78
- P/E Ratio
- MASI N/A
- BPMC N/A
- Revenue Growth
- MASI 16.68
- BPMC 99.19
- 52 Week Low
- MASI $101.61
- BPMC $73.04
- 52 Week High
- MASI $194.88
- BPMC $128.75
- Technical
- Relative Strength Index (RSI)
- MASI 49.72
- BPMC 74.76
- Support Level
- MASI $161.18
- BPMC $128.06
- Resistance Level
- MASI $172.55
- BPMC $128.78
- Average True Range (ATR)
- MASI 4.93
- BPMC 0.26
- MACD
- MASI -0.71
- BPMC -1.13
- Stochastic Oscillator
- MASI 39.58
- BPMC 53.85
About MASI Masimo Corporation
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.